Alcohol use disorder (AUD) is a major public health problem in the United States. The estimated 12-month and lifetime prevalence values for AUD are 13.9% and 29.1%, respectively, with approximately half of individuals with lifetime AUD having a severe disorder. AUD and its sequelae also account for significant excess mortality and cost the United States more than $200 billion annually. Despite its high prevalence and numerous negative consequences, AUD remains undertreated. In fact, fewer than 1 in 10 individuals in the United States with a 12-month diagnosis of AUD receive any treatment. Nevertheless, effective and evidence-based interventions are available, and treatment is associated with reductions in the risk of relapse and AUD-associated mortality.
The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder seeks to reduce these substantial psychosocial and public health consequences of AUD for millions of affected individuals. The guideline focuses specifically on evidence-based pharmacological treatments for AUD in outpatient settings and includes additional information on assessment and treatment planning, which are an integral part of using pharmacotherapy to treat AUD. In addition to reviewing the available evidence on the use of AUD pharmacotherapy, the guideline offers clear, concise, and actionable recommendation statements, each of which is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms. The guideline provides guidance on implementing these recommendations into clinical practice, with the goal of improving quality of care and treatment outcomes of AUD.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Vendeur : PBShop.store UK, Fairford, GLOS, Royaume-Uni
PAP. Etat : New. New Book. Shipped from UK. Established seller since 2000. N° de réf. du vendeur CX-9780890426821
Quantité disponible : 15 disponible(s)
Vendeur : Basi6 International, Irving, TX, Etats-Unis
Etat : Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service. N° de réf. du vendeur ABEOCT25-132431
Quantité disponible : 1 disponible(s)
Vendeur : Rarewaves.com USA, London, LONDO, Royaume-Uni
Paperback. Etat : New. Alcohol use disorder (AUD) is a major public health problem in the United States (U.S.). The estimated 12-month and lifetime prevalence values for AUD are 13.9% and 29.1%, respectively, with approximately half of individuals with lifetime AUD having a severe disorder. AUD and its sequelae also account for significant excess mortality and cost the U.S. over $200 billion annually. Despite its high prevalence and numerous negative consequences, AUD remains undertreated. In fact, fewer than 1 in 10 individuals in the U.S. with a 12-month diagnosis of AUD receive any treatment. Nevertheless, effective and evidence-based interventions are available, and treatment is associated with reductions in the risk of relapse and AUD associated mortality.The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients with Alcohol Use Disorder seeks to reduce these substantial psychosocial and public health consequences of AUD for millions of affected individuals. The guideline focuses specifically on evidence-based pharmacologic treatments for AUD, but also includes statements related to assessment and treatment planning that are an integral part of using pharmacotherapy to treat AUD. The guideline offers clear, concise, and actionable recommendation statements to help clinicians incorporate recommendations into clinical practice, with the goal of improving quality of care and treatment outcomes of AUD. Each recommendation is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms. In addition to reviewing the available evidence on the use of AUD pharmacotherapy in outpatients, the guideline provides guidance to clinicians on implementing these recommendations to enhance patient care. N° de réf. du vendeur LU-9780890426821
Quantité disponible : Plus de 20 disponibles
Vendeur : Revaluation Books, Exeter, Royaume-Uni
Paperback. Etat : Brand New. 214 pages. 10.75x8.25x0.50 inches. In Stock. N° de réf. du vendeur __0890426821
Quantité disponible : 1 disponible(s)
Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
Etat : New. In. N° de réf. du vendeur ria9780890426821_new
Quantité disponible : 2 disponible(s)
Vendeur : THE SAINT BOOKSTORE, Southport, Royaume-Uni
Paperback / softback. Etat : New. New copy - Usually dispatched within 4 working days. N° de réf. du vendeur B9780890426821
Quantité disponible : 1 disponible(s)
Vendeur : moluna, Greven, Allemagne
Etat : New. The guideline focuses specifically on evidence-based pharmacological treatments for AUD in outpatient settings and includes additional information on assessment and treatment planning, which are an integral part of using pharmacotherapy to treat AUD. N° de réf. du vendeur 595129651
Quantité disponible : Plus de 20 disponibles
Vendeur : UK BOOKS STORE, London, LONDO, Royaume-Uni
Etat : New Books. Brand New! Fast Delivery This is an International Edition and ship within 24-48 hours. Deliver by FedEx and Dhl, & Aramex, UPS, & USPS and we do accept APO and PO BOX Addresses. Order can be delivered worldwide within 6-10 days and we do have flat rate for up to 2LB. Extra shipping charges will be requested if the Book weight is more than 5 LB. This Item May be shipped from India, United states & United Kingdom. Depending on your location and availability. N° de réf. du vendeur CBS 9780890426821
Quantité disponible : 5 disponible(s)
Vendeur : Rarewaves.com UK, London, Royaume-Uni
Paperback. Etat : New. Alcohol use disorder (AUD) is a major public health problem in the United States (U.S.). The estimated 12-month and lifetime prevalence values for AUD are 13.9% and 29.1%, respectively, with approximately half of individuals with lifetime AUD having a severe disorder. AUD and its sequelae also account for significant excess mortality and cost the U.S. over $200 billion annually. Despite its high prevalence and numerous negative consequences, AUD remains undertreated. In fact, fewer than 1 in 10 individuals in the U.S. with a 12-month diagnosis of AUD receive any treatment. Nevertheless, effective and evidence-based interventions are available, and treatment is associated with reductions in the risk of relapse and AUD associated mortality.The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients with Alcohol Use Disorder seeks to reduce these substantial psychosocial and public health consequences of AUD for millions of affected individuals. The guideline focuses specifically on evidence-based pharmacologic treatments for AUD, but also includes statements related to assessment and treatment planning that are an integral part of using pharmacotherapy to treat AUD. The guideline offers clear, concise, and actionable recommendation statements to help clinicians incorporate recommendations into clinical practice, with the goal of improving quality of care and treatment outcomes of AUD. Each recommendation is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms. In addition to reviewing the available evidence on the use of AUD pharmacotherapy in outpatients, the guideline provides guidance to clinicians on implementing these recommendations to enhance patient care. N° de réf. du vendeur LU-9780890426821
Quantité disponible : Plus de 20 disponibles